Literature DB >> 3758150

Lack of effect of cimetidine on pharmacodynamics and kinetics of single oral doses of R- and S-acenocoumarol.

H H Thijssen, G M Janssen, L G Baars.   

Abstract

The kinetics and dynamics of single doses (5 mg p.o.) of the optical isomers of acenocoumarol (R-AC and S-AC) were followed in healthy subjects and the effect on them of cimetidine 800 mg/day was also investigated. The AC enantiomers differed greatly in their pharmacokinetics. The mean residence time (MRT) of R-AC was about 10 times longer than that of S-AC, 15 h vs 1.2 h. There was no difference in the volume of distribution. Depression of blood clotting activity (Thrombotest) was observed only after administration of R-AC. The inactivity of S-AC as a vitamin K antagonist must be ascribed to its short MRT. Cimetidine did not affect the acute oral kinetics of R- and S-AC, nor did it affect the anticlotting activity of R-AC. The urinary excretion pattern of the 6- and 7-hydroxylated AC metabolites was not altered during cimetidine treatment. Although the present studies showed no effect of cimetidine on the pharmacokinetics and dynamics of acenocoumarol, the findings of Serlin et al. suggest that cimetidine should not be administered during acenocoumarol therapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3758150     DOI: 10.1007/bf00542424

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Decreased oral warfarin clearance after ranitidine and cimetidine.

Authors:  P V Desmond; M L Mashford; P J Harman; B J Morphett; K J Breen; Y M Wang
Journal:  Clin Pharmacol Ther       Date:  1984-03       Impact factor: 6.875

2.  Factors affecting the response to inhibition of drug metabolism by cimetidine--dose response and sensitivity of elderly and induced subjects.

Authors:  J Feely; L Pereira; E Guy; N Hockings
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

Review 3.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

4.  Statistical moments in pharmacokinetics.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

5.  Stereoselective aspects in the pharmacokinetics and pharmacodynamics of acenocoumarol and its amino and acetamido derivatives in the rat.

Authors:  H H Thijssen; L G Baars; M J Drittij-Reijnders
Journal:  Drug Metab Dispos       Date:  1985 Sep-Oct       Impact factor: 3.922

6.  Comparative interaction of cimetidine and ranitidine with racemic warfarin in man.

Authors:  R A O'Reilly
Journal:  Arch Intern Med       Date:  1984-05

7.  Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations.

Authors:  C Banfield; R O'Reilly; E Chan; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

8.  Pharmacokinetics of the enantiomers of acenocoumarol in man.

Authors:  J Godbillon; J Richard; A Gerardin; T Meinertz; W Kasper; E Jähnchen
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

9.  Cimetidine: interaction with oral anticoagulants in man.

Authors:  M J Serlin; R G Sibeon; S Mossman; A M Breckenridge; J R Williams; J L Atwood; J M Willoughby
Journal:  Lancet       Date:  1979-08-18       Impact factor: 79.321

10.  Metabolic fate of phenprocoumon in humans.

Authors:  S Toon; L D Heimark; W F Trager; R A O'Reilly
Journal:  J Pharm Sci       Date:  1985-10       Impact factor: 3.534

View more
  8 in total

Review 1.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Haematological adverse effects of histamine H2-receptor antagonists.

Authors:  J P Aymard; B Aymard; P Netter; B Bannwarth; P Trechot; F Streiff
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

3.  Cimetidine-nicoumalone interaction in man: stereochemical considerations.

Authors:  T S Gill; K J Hopkins; J Bottomley; S K Gupta; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

Review 4.  Pharmacological importance of stereochemical resolution of enantiomeric drugs.

Authors:  M R Islam; J G Mahdi; I D Bowen
Journal:  Drug Saf       Date:  1997-09       Impact factor: 5.228

5.  Lack of effect of ponsinomycin on the pharmacokinetics of nicoumalone enantiomers.

Authors:  W Couet; B Istin; J P Decourt; I Ingrand; J Girault; J B Fourtillan
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

Review 6.  Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Authors:  Simone Stehle; Julia Kirchheiner; Andreas Lazar; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.

Authors:  J J Hermans; H H Thijssen
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

8.  Vitamin K 2,3-epoxide reductase: the basis for stereoselectivity of 4-hydroxycoumarin anticoagulant activity.

Authors:  H H Thijssen; L G Baars; H T Vervoort-Peters
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.